VarmX
- Biotech or pharma, therapeutic R&D
At VarmX, we are redefining emergency care for patients on FXa inhibitors.
Our lead compound, VMX-C001, is a modified recombinant human factor X that bypasses the anticoagulant effect of FXa direct oral anticoagulants (DOACs) to rapidly and safely restore hemostasis in patients requiring urgent surgery or experiencing severe bleeding. Unlike current agents, VMX-C001 offers universal dosing, compatibility with heparins, and no added thrombotic risk.
We are currently raising a Series C investment round to fund our pivotal Phase 3 clinical trial and prepare for commercial launch by 2028. In parallel, we are actively seeking co-development and strategic partners in Japan.
If you’re looking for a high-impact asset in the anticoagulation space with global potential, let’s connect at BIO.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}